Background: Polycystic ovary syndrome (PCOS) is an endo- crine disorder marked by insulin resistance, hyperglycemia, and reproductive dysfunction. Empagliflozin (EMPA), a sodium- glucose cotransporter 2 (SGLT2) inhibitor, reduces blood glu- cose in type 2 diabetes and may be beneficial for PCOS due to shared metabolic features. This study investigated the effects of empagliflozin on serum and follicular fluid levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testoster- one (T), and estradiol (E2) in women with PCOS. Materials and Methods: Forty women with PCOS were ran- domly divided into two groups. Empagliflozin (25 mg) and placebo (25 mg ORS solution) were both administered for 8 weeks. Treatment was started two months before the oocyte cycle and continued until the day of oocyte retrieval. Finally, serum and follicular fluid LH, FSH, testosterone, and estradiol levels were measured by ELISA (Enzyme-Linked Immunosorb- ent Assay). Data were analyzed using the Independent T-Test, and the difference between means was considered significant at the P<0.05 level. Results: After two months, the empagliflozin group showed a significant reduction in serum and follicular fluid LH levels 79 26 th Hybrid Congress on Reproductive Biomedicine (3-5 September 2025) compared to the placebo group (P<0.001). No significant dif- ferences were found in FSH levels in either serum (P= 0.27) or follicular fluid (P=0.07). While serum estradiol levels were similar between groups (P=0.8), follicular fluid estradiol was significantly lower in the empagliflozin group (P<0.001). Tes- tosterone levels did not differ significantly in serum (P=0.954) or follicular fluid (P=0.910). Conclusion: The results indicated that empagliflozin reduced LH and follicular fluid estradiol levels in women with PCOS, suggesting its potential to improve hormonal imbalances. Fur- ther research is needed to confirm its long-term efficacy and safety.
